NCT04581148: SARS-CoV2_KIDS

SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)

Status unknown Last updated 27 January 2022

What this trial tests

trial testing Blood test antibodies against SARS-CoV-2 in SARS-Cov2 in 7,000 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	7,000
Start date	1 October 2020
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across Germany

Drugs / interventions tested

• Blood test antibodies against SARS-CoV-2

Conditions studied

• SARS-Cov2 — all drugs for SARS-Cov2 →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 1 Minute to 18, any sex, with SARS-Cov2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since the beginning of the year, the entire world has been concerned with the novel SARS-CoV2 virus. After the first case descriptions in Wuhan, there has been a rapid increase in the number of cases in Germany as well. In case of an illness with the virus, the affected patients can suffer from a slight infection of the upper respiratory tract up to severe lung failure and death. Interestingly, up to now, children are usually less severely affected than adults. However, the actual infection rates are probably similar to those of adults, even if the actual prevalence in children is difficult to quantify so far. The extent of the disease in children has also been less researched to date than in adults, and the same applies to pregnant women and their newborns. In addition, intensive research into possible therapeutic strategies and new vaccines is necessary. Here, however, the number of clinical studies in children is also far behind. In order to be able to understand the infection process and to protect the population with their children, comprehensive testing is necessary. However, this poses great challenges for local health authorities. Scientific investigations are also costly, but are already being carried out by many institutes. So far, for example in the SeBlueCo study, a very low prevalence of antibodies (1.3% of people) has been show. In children, however, both the routes of infection and the way the immune system deals with the virus are probably different than in adults. In this study the investigators now want to examine residual blood samples from pediatric patients of the pediatric and adolescent clinic in the time course after the beginning of the pandemic in order to better understand and monitor the development of antibody prevalence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response.
   Wachter F, Knieling F, Raming R, Simon D, et al · · 2023 · PMID 38138063 · DOI 10.3390/microorganisms11122919